Abstract Introduction High-dose melphalan (HDMel) is the most common conditioning
chemotherapy regimen for autologous stem cell transplantation (SCT) in patients affected by …

We have read with great interest the paper by Trifilio and colleagues, 1 entitled “Olanzapine
Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in …

Background Limited data are available regarding efficacious antiemetic regimens to prevent
chemotherapy-induced nausea and vomiting (CINV) for patients undergoing allogeneic …

Introduction Acute and delayed chemotherapy-induced nausea and vomiting (CINV) occurs
in most patients who receive high-dose melphalan and significantly affects patients' quality …

High-dose melphalan has been gaining recognition as a highly emetogenic agent used in
hematopoietic stem cell transplantation (HSCT). The aim of this retrospective study was to …

Objective: To evaluate the clinical and cost benefits of the administration of aprepitant for the
prophylaxis of chemotherapy-induced nausea and vomiting (CINV) during high-dose …

OBJECTIVE: We performed a clinical study of a triple-drug combination to evaluate its
efficacy to prevent both acute and delayed emesis after high-dose chemotherapy with BEAM …

Chemotherapy-induced nausea and vomiting (CINV) is a significant side effect in multiple
myeloma (MM) patients receiving high-dose melphalan treatment followed by autologous …

Chemotherapy-induced nausea and vomiting (CINV) is common in patients with lymphoma
and multiple myeloma (MM) receiving high-dose chemotherapy (HDC) followed by …

Purpose The optimal regimen to prevent chemotherapy-induced nausea and vomiting
(CINV) for patients undergoing high-dose chemotherapy and autologous stem-cell …